FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1061-1063 March 6, 2008 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Schwarz, U. I. PubMed Citation

It cannot be emphasized too strongly that treatment of each patient is a highly individualized matter.

— FDA-approved labeling for warfarin (Coumadin) NDA 9-218/5-105

Pharmacogenomics is receiving a great deal of attention in scientific circles and, increasingly, in the popular press because of the promise of personalized medicine. Short of being able to cure an illness or to prevent one, every clinician's dream is to offer patients a precisely targeted drug at a precisely calibrated dose to address a specific ailment — and to do so without wreaking havoc on the rest of the body. We have ample reason to . . . [Full Text of this Article]

Source Information

From the National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.

This article has been cited by other articles:

• Wolverton, S. E. (2009). Optimizing Clinical Use of Azathioprine With Newer Pharmacogenetic Data. Arch Dermatol 145: 707-710 [Full Text]  
• Garber, A. M., Tunis, S. R. (2009). Does Comparative-Effectiveness Research Threaten Personalized Medicine?. NEJM 360: 1925-1927 [Full Text]  
• Roden, D. M., Stein, C. M. (2009). Clopidogrel and the Concept of High-Risk Pharmacokinetics. Circulation 119: 2127-2130 [Full Text]  
• Li, C., Schwarz, U. I., Ritchie, M. D., Roden, D. M., Stein, C. M., Kurnik, D. (2009). Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113: 3925-3930 [Abstract] [Full Text]  
• The International Warfarin Pharmacogenetics Consor, (2009). Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. NEJM 360: 753-764 [Abstract] [Full Text]  
• Schillinger, D., Neville, K. A., Wicklund, B. M., Kearns, G. L., Kulkarni, U. P., Karnad, D. R., Gogtay, N. J., Mannucci, P. M., Spreafico, M., Peyvandi, F., Stein, C. M., Roden, D. M., Schwarz, U. I. (2008). Genetics of Warfarin Response. NEJM 358: 2741-2744 [Full Text]